NCT05071937View on ClinicalTrials.gov

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 21, 2023

Primary Completion Date

December 31, 2031

Study Completion Date

March 1, 2033

Conditions
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Interventions
DRUG

ZEN003694

ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.

DRUG

Talazoparib

Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.

Trial Locations (1)

15213

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

Sponsors

Collaborators (2)

Pfizer
Zenith Epigenetics
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Zenith Epigenetics

INDUSTRY

lead

Alexander B Olawaiye, MD

OTHER